Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma.

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

To date, the Food and Drug Administration (FDA) has approved seven chimeric antigen receptor-T (CAR-T) cell therapies and seven bispecific T-cell engagers (BiTEs) across a variety of hematologic ...

This revolutionary approach has given hope to patients who previously had limited or no options, particularly those battling ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

In the last decade, a new immunotherapy tool has entered the clinic. T cells engineered to express chimeric antigen receptors, known as CAR T cells, have been shown to help patients with blood cancer.

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...

GloboCare announced that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell ...

This trend reflects the broader shift in oncology towards precision medicine, where treatments are designed to target specific molecular markers in cancer cells. The growing focus on CAR-T (Chimeric ...